Effect of USP22 on gemcitabine chemoresistance in human pancreatic cancer cell

Abstract

Abstract:

AIM: To evaluate the potential effect of USP22 on gemcitabine chemoresistance in pancreatic cancer cells. METHODS: USP22 expression was detected by Western blot in pancreatic cancer cell lines PANC-1 and SW1990 treated with gemcitabine. The IC50 values of different pancreatic cancer cells to gemcitabine were detected by cell counting kit 8 (CCK-8) assays. RESULTS: USP22 expression was induced by certain dose of gemcitabine treatment in pancreatic cancer cells. CCK-8 assay demonstrated that the IC50 values in SW1990-NC group and SW1990-shUSP22 group were (1 850.96±87.37) nmol/L and (534.83±49.68) nmol/L, respectively. Furthermore, the IC50 values in SW1990-NC, SW1990/Gem-NC and SW1990/Gem-shUSP22 groups were (1 387.58±96.56) nmol/L, (29 850.96±345.78) nmol/L and (2 157.08±120.32) nmol/L, respectively. CONCLUSION: Gemcitabine treatment increases the expression of USP22 in pancreatic cancer cells. Knock-down USP22 expression could enhance the chemosensitivity to gemcitabine in pancreatic cancer cells, but also rescue the gemcitabine resistance in pancreatic cancer cells.

Key words: USP22, pancreatic cancer, gemcitabine, resistance

CLC Number:

R965.2

WANG Wanming, DONG Jiazhong, GUAN Shuming. Effect of USP22 on gemcitabine chemoresistance in human pancreatic cancer cell[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 412-417.

References

［1］David M,Lepage C,Jouve JL,et al.Management and prognosis of pancreatic cancer over a 30-year period［J］. Br J Cancer,2009,101(2):215-218.
［2］linsky GV, Berezovska O, Glinskii AB. Mieroarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer［J］.J Clin Invest, 2005,115(6):1503-1521.
［3］Atanassov BS, Dent SY. USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBPl ［J］. EMBO Rep, 2011, 12(9):924-930.
［4］牛备战，陈革，李丽君，等. 吉西他滨诱导胰腺癌细胞株SWl990/GZ的耐药作用与硫氧还蛋白还原酶活性的改变［J］．中国医学科学院学报，2005，27(5): 606-610.
［5］贾一夫，丁飞，余跃，高萌，杨显珠，王均. 吉西他滨耐药的胰腺癌SW1990细胞株的建立及相关特性检测［J］. 安徽医科大学学报，2015, 50(4): 419-422.
［6］Zhang XY, Varthi M, Sykes SM, et al. The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression ［J］. Mol Cell, 2008, 29(1): 102-111.
［7］Zhang XY, Pfeiffer HK, Thorne AW, et al. USP22, an hSAGA subunit and potential cancer stem cellmarker, reverses the polycomb-catalyzed ubiquitylation of histone H2A［J］. Cell Cycle, 2008, 7(11): 1522-1524.
［8］Ning Z, Wang A, Liang J, et al. USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via β-catenin nuclear localization and is associated with poor prognosis in stage II pancreatic ductal adenocarcinoma［J］. Int J Oncol, 2014, 45(4): 1594-1608.
［9］de Sousa Cavalcante L, Monteiro G. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer ［J］.Eur J Pharmacol, 2014, 741:8-16.
［10］Li ZH, Yu Y, Du C, et al. RNA interference-mediated USP22 gene silencing promotes human brain glioma apoptosis and induces cell cycle arrest ［J］. Oncol Lett, 2013, 5(4): 1290-1294.
［11］Zhang M, Fan HY, Li SC. Inhibition of c-Myc by 10058-F4 induces growth arrest and chemosensitivity in pancreatic ductal adenocarcinoma ［J］. Biomed Pharmacother, 2015, 73:123-128.

[1]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[2]	ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin. Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
[3]	ZHANG Jinghui, WEI Haoliang, WANG Li, LI Jingkai, ZHANG Baolai, YANG Xiaolai. Effects of AMI-1 on the activity of pancreatic cancer cells in vitro by down-regulating PRMT5 expression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 601-608.
[4]	HE Yang, YANG Kui, LUAN Jiajie. Effects of CDA-G208A gene polymorphism on the efficacy of gem-citabine in the first-line treatment of lung squamous cell carcinoma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 299-306.
[5]	LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing. Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340.
[6]	ZHANG Wei, WANG Hongyuan, LEI Xiaohang, ZHAO Yingshuai, LV Weichao, ZHANG Jianguo. BCG + piroxicam versus BCG + gemcitabine for prevention of postoperative recurrence in intermediate- and high-risk bladder cancer and effects on serum AGR and PON1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1146-1153.
[7]	LIU Jiajia, GAO Yan, ZHANG Yehui, WU Jing. Functions of CRABP2 in tumorigenesis and progression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 86-92.
[8]	ZHOU Huan, XU Ming, LI Bo, LIU Chunying, WANG Chun. PI3K/Akt/FOXO3a signaling pathway inducing protective autophagy promotes acquired lung adenocarcinoma resistance remodeling to DDP [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 961-970.
[9]	ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali. Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1016-1030.
[10]	YE Xiaodi, MIAO Yunping, CHEN Aiying, CHENG Min, TIAN Xuejun, ZHENG Gaoli . Optimization and verification of orthotopic non-muscle invasive bladder cancer model in nude mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 473-480.
[11]	DONG Wei, HUANG Xiaoying, XIE Bingbin, TANG Xilan, LI Hongming, QIU Yumei, ZHAO Guowei, LIANG Xinli. Effects of oxypeucedanin on the resistance of breast cancer MCF-7/DOX cells to doxorubicin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 260-266.
[12]	QUAN Haiyan, JIANG Xing, HE Lu. Recent progress of mitophagy in hepatic insulin resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 198-204.
[13]	ZHENG Ying, ZHANG Ling, YAO Li, WANG Qianhe, ZHU Kexiang. Research progress of PARP inhibitors in pancreatic cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 108-115.
[14]	MENG Qiang, LIU Kexin. Research status and prospect of transporter-mediated drug-drug interactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 876-888.
[15]	YU Saihong, ZHENG Xiaoliang, PU Yiyi, YAN Dongmei, WANG Xiaoju, YU Jie. Reversal of 5-fluorouracil resistance in hepatocellular carcinoma cells by inhibiting ribonucleotide reductase M2 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 729-737.